|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01931 IVD MEDICAL
Nominal 
1.810 +0.010 (+0.556%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 3,088,387 | 12.354% | 2,748,809 | 2,730,670 | 2,428,210 | 2,332,740 |
| Cost of Sales | (2,416,686) | 12.894% | (2,140,668) | (2,164,402) | (1,952,045) | (1,889,862) |
| Gross Profit | 671,701 | 10.452% | 608,141 | 566,268 | 476,165 | 442,878 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (20,631) | 80.105% | (11,455) | 13,918 | 4,542 | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | 167,269 | |
| Share of Results of Asso. & JCEs | (22,659) | -- | 2,795 | 8,335 | 577 | 2,379 | |
| Profit / (Loss) before Taxation | 339,329 | 19.571% | 283,789 | 267,940 | 231,956 | 296,940 | |
| Taxation | (102,203) | 15.799% | (88,259) | (106,190) | (77,338) | (42,121) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 1,037 | -92.833% | 14,469 | 12,791 | 4,100 | 20,182 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 238,163 | 13.411% | 209,999 | 174,541 | 158,718 | 275,001 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 18,130 | -36.626% | 28,608 | 18,664 | 21,644 | 3,528 |
| Depreciation & Amortisation | 37,559 | 6.433% | 35,289 | 38,806 | 37,764 | 49,437 |
| Directors' Emoluments | 8,928 | -19.050% | 11,029 | 10,666 | 28,522 | 27,234 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 17.620 | 12.876% | 15.610 | 13.190 | 11.930 | 24.250 |
| DPS (cts) | 8.325 | -- | 7.251 | 6.602 | 4.431 | 4.875 |
| Dividend Payout Ratio (%) | 47.247% | -- | 46.451% | 50.052% | 37.141% | 20.105% |
| Cash flow per share ($) | 0.216 | -- | 0.186 | 0.123 | 0.128 | 0.301 |
| NBV per share ($) | 2.469 | -- | 2.328 | 2.202 | 2.155 | 2.114 |
| Remarks: | Real time quote last updated: 25/11/2024 09:42 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 125,288 |
| %Change | 21.628% |
| EPS / (LPS) | RMB 0.093 |
| NBV Per Share (¥) | RMB 2.505 |